InvestorsObserver
×
News Home

What is the Market's View on Amgen, Inc. (AMGN) Stock's Price and Volume Trends Wednesday?

Wednesday, November 24, 2021 12:11 PM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on Amgen, Inc. (AMGN) Stock's Price and Volume Trends Wednesday?

The market has been neutral on Amgen, Inc. (AMGN) stock recently. AMGN gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,neutral
Amgen, Inc. has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on AMGN!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With AMGN Stock Today?

Amgen, Inc. (AMGN) stock is trading at $204.02 as of 11:53 AM on Wednesday, Nov 24, a loss of -$0.51, or -0.25% from the previous closing price of $204.53. The stock has traded between $202.95 and $205.28 so far today. Volume today is less active than usual. So far 483,445 shares have traded compared to average volume of 2,759,840 shares. To screen for more stocks like Amgen, Inc. click here.

More About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), and Lumakras (lung cancer). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira). Click Here to get the full Stock Report for Amgen, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App